Compare MAGN & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | PRTC |
|---|---|---|
| Founded | 1864 | 2015 |
| Country | United States | United States |
| Employees | 8500 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.8M | 464.3M |
| IPO Year | N/A | N/A |
| Metric | MAGN | PRTC |
|---|---|---|
| Price | $11.43 | $16.81 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 360.0K | 3.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.09 | N/A |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.82 | $13.30 |
| 52 Week High | $20.03 | $20.00 |
| Indicator | MAGN | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 28.43 | 48.59 |
| Support Level | $10.52 | $16.51 |
| Resistance Level | $12.09 | $18.10 |
| Average True Range (ATR) | 0.49 | 0.49 |
| MACD | -0.18 | -0.08 |
| Stochastic Oscillator | 16.50 | 44.66 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.